Matinas BioPharma Receives NYSE Warning
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: seekingalpha
- Insufficient Shareholder Equity: Matinas BioPharma reported a shareholder equity of $3.02 million as of March 2026, falling below the NYSE's required threshold of $4 million, highlighting the company's ongoing financial struggles with losses over the past five years.
- Compliance Plan Approved: The NYSE has accepted Matinas's plan to address the equity shortfall, granting the company until October 2, 2027, to regain compliance, indicating the exchange's expectation for potential recovery.
- Potential Delisting Risk: Should Matinas fail to improve its financial position within the stipulated timeframe, its shares could face delisting, which would negatively impact investor confidence and the company's market performance.
- Operations Unaffected: Despite receiving the warning notice, the company’s daily operations and stock trading remain unaffected for now, suggesting that Matinas can continue its normal business activities in the short term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTNB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTNB
About MTNB
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Matinas BioPharma Faces NYSE Compliance Challenges
- Compliance Notice: On June 24, 2026, Matinas BioPharma received a notice from NYSE American indicating non-compliance with listing standards due to stockholders' equity falling below $4 million, highlighting ongoing financial health challenges for the company.
- Declining Equity: As of March 31, 2026, Matinas reported stockholders' equity of $3.02 million, a significant drop from $4.83 million as of December 31, 2025, reflecting the harsh reality of sustained losses over the past five fiscal years.
- Compliance Plan Submission: Following the non-compliance notice, Matinas submitted a compliance plan to the NYSE on May 4, 2026, which was accepted, allowing the company to maintain its listing until October 2, 2027, indicating proactive measures to regain compliance.
- Drug Development Progress: Matinas's lead investigational drug, MAT2203, met its primary endpoint in a clinical trial for HIV patients, with plans for further evaluation in invasive aspergillosis patients, showcasing the company's potential and hope in the biopharmaceutical sector.
See More
Matinas BioPharma Receives NYSE Warning
- Insufficient Shareholder Equity: Matinas BioPharma reported a shareholder equity of $3.02 million as of March 2026, falling below the NYSE's required threshold of $4 million, highlighting the company's ongoing financial struggles with losses over the past five years.
- Compliance Plan Approved: The NYSE has accepted Matinas's plan to address the equity shortfall, granting the company until October 2, 2027, to regain compliance, indicating the exchange's expectation for potential recovery.
- Potential Delisting Risk: Should Matinas fail to improve its financial position within the stipulated timeframe, its shares could face delisting, which would negatively impact investor confidence and the company's market performance.
- Operations Unaffected: Despite receiving the warning notice, the company’s daily operations and stock trading remain unaffected for now, suggesting that Matinas can continue its normal business activities in the short term.
See More
Matinas BioPharma Faces NYSE Compliance Issues
- Compliance Notice: Matinas BioPharma received a notice from NYSE American on April 2, 2026, indicating non-compliance with the listing standard under Section 1003(a)(i), posing significant compliance risks.
- Insufficient Shareholder Equity: The notice revealed that the company had shareholder equity of $4.83 million as of December 31, 2025, failing to meet the minimum equity requirements of $2 million, $4 million, or $6 million based on loss history.
- Compliance Plan Deadline: The company must submit a compliance plan by May 2, 2026, and has up to 18 months from the notice date to regain compliance, which could significantly impact its future operations.
- Increased Financial Pressure: With continuous losses over the past five fiscal years, Matinas BioPharma has lost any exemption eligibility under Section 1003(a), potentially facing further financial and operational challenges.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
US Stocks Show Varied Performance; Riskified Shares Decline Following Q2 Earnings Report
Market Overview: U.S. stocks showed mixed results, with the Dow and NASDAQ slightly up while the S&P 500 fell by 0.03%.
Sector Performance: Information technology shares increased by 0.3%, whereas energy stocks dropped by 1.1%.
Notable Stock Movements: Riskified shares fell 13% despite meeting earnings expectations, while Propanc Biopharma surged 210% after uplisting to Nasdaq.
Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.1%, while Asian markets mostly closed higher, led by Japan's Nikkei 225 gaining 0.77%.
See More
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Board Appointments: Matinas BioPharma has appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors, effective March 11, 2025, while thanking departing directors Matthew Wikler and Natasha Giordano for their service.
Product Development: The company is advancing its oral antifungal treatment MAT2203, which aims to provide a safer alternative to intravenous amphotericin B, having successfully completed a Phase 2 study in HIV patients with cryptococcal meningitis and planning further evaluation in a Phase 3 trial.
See More
Matinas BioPharma Faces NYSE Compliance Challenges
- Compliance Notice: On June 24, 2026, Matinas BioPharma received a notice from NYSE American indicating non-compliance with listing standards due to stockholders' equity falling below $4 million, highlighting ongoing financial health challenges for the company.
- Declining Equity: As of March 31, 2026, Matinas reported stockholders' equity of $3.02 million, a significant drop from $4.83 million as of December 31, 2025, reflecting the harsh reality of sustained losses over the past five fiscal years.
- Compliance Plan Submission: Following the non-compliance notice, Matinas submitted a compliance plan to the NYSE on May 4, 2026, which was accepted, allowing the company to maintain its listing until October 2, 2027, indicating proactive measures to regain compliance.
- Drug Development Progress: Matinas's lead investigational drug, MAT2203, met its primary endpoint in a clinical trial for HIV patients, with plans for further evaluation in invasive aspergillosis patients, showcasing the company's potential and hope in the biopharmaceutical sector.
See More
Matinas BioPharma Receives NYSE Warning
- Insufficient Shareholder Equity: Matinas BioPharma reported a shareholder equity of $3.02 million as of March 2026, falling below the NYSE's required threshold of $4 million, highlighting the company's ongoing financial struggles with losses over the past five years.
- Compliance Plan Approved: The NYSE has accepted Matinas's plan to address the equity shortfall, granting the company until October 2, 2027, to regain compliance, indicating the exchange's expectation for potential recovery.
- Potential Delisting Risk: Should Matinas fail to improve its financial position within the stipulated timeframe, its shares could face delisting, which would negatively impact investor confidence and the company's market performance.
- Operations Unaffected: Despite receiving the warning notice, the company’s daily operations and stock trading remain unaffected for now, suggesting that Matinas can continue its normal business activities in the short term.
See More
Matinas BioPharma Faces NYSE Compliance Issues
- Compliance Notice: Matinas BioPharma received a notice from NYSE American on April 2, 2026, indicating non-compliance with the listing standard under Section 1003(a)(i), posing significant compliance risks.
- Insufficient Shareholder Equity: The notice revealed that the company had shareholder equity of $4.83 million as of December 31, 2025, failing to meet the minimum equity requirements of $2 million, $4 million, or $6 million based on loss history.
- Compliance Plan Deadline: The company must submit a compliance plan by May 2, 2026, and has up to 18 months from the notice date to regain compliance, which could significantly impact its future operations.
- Increased Financial Pressure: With continuous losses over the past five fiscal years, Matinas BioPharma has lost any exemption eligibility under Section 1003(a), potentially facing further financial and operational challenges.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
US Stocks Show Varied Performance; Riskified Shares Decline Following Q2 Earnings Report
Market Overview: U.S. stocks showed mixed results, with the Dow and NASDAQ slightly up while the S&P 500 fell by 0.03%.
Sector Performance: Information technology shares increased by 0.3%, whereas energy stocks dropped by 1.1%.
Notable Stock Movements: Riskified shares fell 13% despite meeting earnings expectations, while Propanc Biopharma surged 210% after uplisting to Nasdaq.
Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.1%, while Asian markets mostly closed higher, led by Japan's Nikkei 225 gaining 0.77%.
See More
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Board Appointments: Matinas BioPharma has appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors, effective March 11, 2025, while thanking departing directors Matthew Wikler and Natasha Giordano for their service.
Product Development: The company is advancing its oral antifungal treatment MAT2203, which aims to provide a safer alternative to intravenous amphotericin B, having successfully completed a Phase 2 study in HIV patients with cryptococcal meningitis and planning further evaluation in a Phase 3 trial.
See More
